EXPERIENCE

Thomas Malley is President of Mossrock Capital, a private investment firm through which he invests across public equities and venture capital, primarily in healthcare. He also serves on the boards of Kura Oncology and Kiniksa Pharmaceuticals and as chair of Project C.U.R.E., a nonprofit supplier of donated medical equipment to resource-limited countries.

Prior to founding Mossrock Capital, Thomas spent 16 years at Janus Capital Group, where he progressed from healthcare and biotechnology equity analyst to portfolio manager of the Janus Global Life Sciences Fund and leader of the firm’s healthcare research team.

Thomas has served on the boards of numerous biotechnology and healthcare organizations, including BeOne Medicines, formerly BeiGene, OvaScience, Puma Biotechnology, Synageva BioPharma, Cougar Biotechnology, Craig Hospital and St. Anthony Health Foundation. During his board tenure, Synageva was acquired by Alexion and Cougar Biotechnology was acquired by Johnson & Johnson.

EDUCATION

Thomas received a B.S. in Biology from Stanford University.